397 related articles for article (PubMed ID: 9142958)
1. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
Lykkesfeldt AE
Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
[TBL] [Abstract][Full Text] [Related]
2. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
[TBL] [Abstract][Full Text] [Related]
3. [Molecular aspects of different mechanisms of tamoxifen resistance].
Bachmann-Moisson N; Barberi-Heyob M; Merlin JL
Bull Cancer; 1997 Jan; 84(1):69-75. PubMed ID: 9180863
[TBL] [Abstract][Full Text] [Related]
4. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.
McClelland RA; Manning DL; Gee JM; Anderson E; Clarke R; Howell A; Dowsett M; Robertson JF; Blamey RW; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 1996; 41(1):31-41. PubMed ID: 8932874
[TBL] [Abstract][Full Text] [Related]
5. In search of the perfect SERM: beyond tamoxifen and raloxifene.
McNeil C
J Natl Cancer Inst; 1998 Jul; 90(13):956-7. PubMed ID: 9665139
[No Abstract] [Full Text] [Related]
6. Differences in immunoreactivity of estrogen receptor (ER) in tamoxifen-sensitive and -resistant breast carcinomas: preclinical and first clinical investigations.
Naundorf H; Jost-Reuhl B; Becker M; Reuhl T; Neumann C; Fichtner I
Breast Cancer Res Treat; 2000 Mar; 60(1):81-92. PubMed ID: 10845812
[TBL] [Abstract][Full Text] [Related]
7. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
8. Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer.
Kulkoyluoglu E; Madak-Erdogan Z
Steroids; 2016 Oct; 114():41-47. PubMed ID: 27394959
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of tamoxifen resistance.
Ring A; Dowsett M
Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444
[TBL] [Abstract][Full Text] [Related]
10. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
11. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG
Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440
[TBL] [Abstract][Full Text] [Related]
12. A new marker of tamoxifen resistance of estrogen receptor-positive breast cancer.
Bogush EA; Ravcheeva AB; Bogush TA; Zabotina TN; Kadagidze ZG; Davydov MI
Dokl Biochem Biophys; 2007; 413():83-7. PubMed ID: 17546960
[No Abstract] [Full Text] [Related]
13. Searching for the ideal SERM.
Poletti A
Pharmacol Res; 1999 May; 39(5):333. PubMed ID: 10328989
[No Abstract] [Full Text] [Related]
14. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
15. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS
Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen resistance in breast cancer: elucidating mechanisms.
Dorssers LC; Van der Flier S; Brinkman A; van Agthoven T; Veldscholte J; Berns EM; Klijn JG; Beex LV; Foekens JA
Drugs; 2001; 61(12):1721-33. PubMed ID: 11693462
[TBL] [Abstract][Full Text] [Related]
17. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells.
Brinkman A; van der Flier S; Kok EM; Dorssers LC
J Natl Cancer Inst; 2000 Jan; 92(2):112-20. PubMed ID: 10639512
[TBL] [Abstract][Full Text] [Related]
18. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
19. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
[TBL] [Abstract][Full Text] [Related]
20. Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer.
Kenny FS; Willsher PC; Gee JM; Nicholson R; Pinder SE; Ellis IO; Robertson JF
Breast Cancer Res Treat; 2001 Jan; 65(2):135-44. PubMed ID: 11261829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]